Jung Kyung Hee, Kim Sang Eun, Go Han Gyeol, Lee Yun Ji, Park Min Seok, Ko Soyeon, Han Beom Seok, Yoon Young-Chan, Cho Ye Jin, Lee Pureunchowon, Lee Sang-Ho, Kim Kipyo, Hong Soon-Sun
Department of Medicine, College of Medicine, and Program in Biomedical Science & Engineering, Inha University, Incheon 22332, Republic of Korea.
Division of Nephrology, Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul 02453, Republic of Korea.
Biomol Ther (Seoul). 2023 Nov 1;31(6):599-610. doi: 10.4062/biomolther.2023.062. Epub 2023 May 15.
According to recent evidence, ferroptosis is a major cell death mechanism in the pathogenesis of kidney injury and fibrosis. Despite the renoprotective effects of classical ferroptosis inhibitors, therapeutic approaches targeting kidney ferroptosis remain limited. In this study, we assessed the renoprotective effects of melatonin and zileuton as a novel therapeutic strategy against ferroptosis-mediated kidney injury and fibrosis. First, we identified RSL3-induced ferroptosis in renal tubular epithelial HK-2 and HKC-8 cells. Lipid peroxidation and cell death induced by RSL3 were synergistically mitigated by the combination of melatonin and zileuton. Combination treatment significantly downregulated the expression of ferroptosis-associated proteins, 4-HNE and HO-1, and upregulated the expression of GPX4. The expression levels of p-AKT and p-mTOR also increased, in addition to that of NRF2 in renal tubular epithelial cells. When melatonin (20 mg/kg) and zileuton (20 mg/kg) were administered to a unilateral ureteral obstruction (UUO) mouse model, the combination significantly reduced tubular injury and fibrosis by decreasing the expression of profibrotic markers, such as α-SMA and fibronectin. More importantly, the combination ameliorated the increase in 4-HNE levels and decreased GPX4 expression in UUO mice. Overall, the combination of melatonin and zileuton was found to effectively ameliorate ferroptosis-related kidney injury by upregulating the AKT/mTOR/ NRF2 signaling pathway, suggesting a promising therapeutic strategy for protection against ferroptosis-mediated kidney injury and fibrosis.
根据最近的证据,铁死亡是肾损伤和纤维化发病机制中的一种主要细胞死亡机制。尽管经典的铁死亡抑制剂具有肾脏保护作用,但针对肾脏铁死亡的治疗方法仍然有限。在本研究中,我们评估了褪黑素和齐留通作为一种针对铁死亡介导的肾损伤和纤维化的新型治疗策略的肾脏保护作用。首先,我们在肾小管上皮HK-2和HKC-8细胞中鉴定了RSL3诱导的铁死亡。褪黑素和齐留通的组合协同减轻了RSL3诱导的脂质过氧化和细胞死亡。联合治疗显著下调了铁死亡相关蛋白4-HNE和HO-1的表达,并上调了GPX4的表达。肾小管上皮细胞中p-AKT、p-mTOR以及NRF2的表达水平也有所增加。当将褪黑素(20 mg/kg)和齐留通(20 mg/kg)给予单侧输尿管梗阻(UUO)小鼠模型时,该组合通过降低诸如α-SMA和纤连蛋白等促纤维化标志物的表达,显著减轻了肾小管损伤和纤维化。更重要的是,该组合改善了UUO小鼠中4-HNE水平的升高并降低了GPX4的表达。总体而言,发现褪黑素和齐留通的组合通过上调AKT/mTOR/NRF2信号通路有效减轻了铁死亡相关的肾损伤,提示这是一种针对铁死亡介导的肾损伤和纤维化的有前景的治疗策略。